Live-attenuated Zika virus vaccine candidate
Patentne leiutis: Live-attenuated Zika virus vaccine candidate; Omanikud: Tartu Ülikool, Loodus- ja täppisteaduste valdkond, tehnoloogiainstituut; Autorid: Andres Merits, Eva Žusinaite, Suresh Mahalingam; Prioriteedi number: No. 2018903913; Prioriteedi kuupäev: 16.10.2018.
Patentne leiutis
Live-attenuated Zika virus vaccine candidate
Live-attenuated Zika virus vaccine candidate
This invention generally relates to a codon deoptimized Zika virus genome. In particular, embodiments of the invention concern a vaccine comprising live attenuated Zika virus comprising a partly codon deoptimized viral genome, a Zika virus comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection
This invention generally relates to a codon deoptimized Zika virus genome. In particular, embodiments of the invention concern a vaccine comprising live attenuated Zika virus comprising a partly codon deoptimized viral genome, a Zika virus comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection
Lisainfo: Jane Luht Maris Astel sekretär Tartu Ülikool ettevõtlus- ja innovatsioonikeskus Lossi 3-323 7374809 maris.astel@ut.ee
Prioriteeditaotlus
16.10.2018
No. 2018903913
Muu ...
Tegemist on taotlusega seega ei ole ükski Staatus valikutest rakendatav. Kuna midagi peab valima on valitud "Kaitstud" ehkki see pole tõsi.
Australian Provisional Patent Application No. 2018903913
Austraalia patendiamet
Austraalia
Kaitstud